Understanding ROS1 Fusion in Lung Cancer

ROS1 (Receptor Tyrosine Kinase) fusion mutations occur in approximately 1-2% of non-small cell lung cancers (NSCLC). While less common than ALK or EGFR mutations, ROS1+ patients benefit from highly effective targeted therapies, particularly entrectinib and crizotinib.

1-2%

of NSCLC patients

ROS1 Fusion

Rare but actionable biomarker

2 FDA-approved

ROS1 inhibitors

High response rates

60-80% with ROS1 inhibitors

ROS1 Fusion Partners

ROS1 fuses with various partner genes, with CD74-ROS1 being the most common. Each fusion partner may have slightly different clinical and treatment characteristics:

CD74-ROS1 (30-40%)

Most common ROS1 fusion partner, highly responsive to crizotinib and entrectinib.

EZR-ROS1 (20-30%)

Second most common, shows good response to ROS1 inhibitors.

LRIG3-ROS1 & Others

Additional partners including TPM3-ROS1, KDELR2-ROS1, and others with varying prevalence.

Treatment Pathways for ROS1+ NSCLC

First-Line Therapy

Entrectinib (Rozlytrek) - Preferred first-line choice
Crizotinib (Xalkori) - Dual ALK/ROS1 inhibitor
Excellent CNS penetration (important for brain metastases)
Response rates 60-80% with ROS1 inhibitors

Post-First-Line Therapy

Switching between entrectinib and crizotinib
Next-generation ROS1 inhibitors in development
Chemotherapy + immunotherapy combinations
Trials targeting resistance mechanisms

CNS-Active Strategies

Entrectinib and crizotinib both cross blood-brain barrier
Effective for brain metastases and leptomeningeal disease
Trials combining ROS1 inhibitors with radiation
Intrathecal chemotherapy options for specific cases

Resistance Management

Secondary ROS1 mutations may confer resistance
Next-generation ROS1 inhibitors for resistant mutations
Combination therapy trials addressing resistance
Trials for bypass signaling pathways

Frequently Asked Questions

How is ROS1 fusion different from ALK fusion? +

ROS1 and ALK are different genes that can be rearranged in lung cancer. While both are rare (~1-5% of NSCLC each), they have distinct fusion partners and drug sensitivities. Some drugs (like crizotinib) target both, but entrectinib is ROS1-specific and shows superior outcomes. Genetic testing can distinguish between the two.

Why is entrectinib preferred over crizotinib for ROS1+ patients? +

Entrectinib (Rozlytrek) was specifically developed for ROS1+ patients and shows superior efficacy and CNS penetration compared to crizotinib. In clinical trials, entrectinib demonstrated higher response rates and longer progression-free survival, making it the preferred first-line choice for most ROS1+ patients with NSCLC.

What is the prognosis for ROS1+ lung cancer patients? +

ROS1+ patients treated with targeted inhibitors like entrectinib or crizotinib have favorable outcomes compared to historical chemotherapy results. Median progression-free survival ranges from 12-24+ months depending on the drug and patient factors. Early diagnosis and treatment with appropriate ROS1 inhibitors significantly improves prognosis.

Can ROS1 inhibitors treat brain metastases? +

Yes, both entrectinib and crizotinib have good blood-brain barrier penetration and can effectively treat brain metastases without requiring separate CNS-directed therapy. This is a significant advantage for ROS1+ patients with asymptomatic brain metastases, allowing for single-agent systemic therapy.

ROS1 Fusion Lung Cancer